Neurocrine Biosciences (NASDAQ: NBIX) announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results October 8, 2015 2:49 PM Neurocrine Bio. (NBIX) PT Bumped to $66 at Baird on NBI-98854 Phase 3 SuccessOctober 8, 2015 1:44 PM Neurocrine Bio. (NBIX) Bullish Stance Reiterated at CowenOctober 8, 2015 12:46 PM Neurocrine Bio (NBIX) PT Raised to $96 at Piper JaffrayOctober 8, 2015 10:52 AM Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive DyskinesiaOctober 8, 2015 6:30 AM